All cancer types
Results
Phase 1
This trial was looking at a treatment called ATN-224 for advanced solid tumours (not lymphoma or leukaemia). This trial was supported by Cancer Research UK.
ATN-224 is an anti angiogenic drug. This means that it stops new blood vessels growing.
ATN-224 works by binding to copper in the body. Cancer cells need copper to grow new blood vessels. So if there is less copper, the cancer cannot form new blood vessels. This will not directly kill the cancer cells, but it will hopefully stop or slow down the growth of the cancer.
The first few people who took part in this trial had the lowest dose of ATN-224. The next few people had a higher dose. And so on until the trial team found the best dose to give. This is called a dose escalation study.
The aims of this trial were to
Find the best dose of ATN-224 to give
See what the side effects are
Find out more about how ATN-224 works
Recruitment start: 6 April 2004
Recruitment end: 10 January 2006
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Adrian Harris
Attenuon
Cancer Research UK (Centre for Drug Development)
Experimental Cancer Medicine Centre (ECMC)
This is Cancer Research UK trial number CRUKD/04/039.
We have more information about the work of Professor Adrian Harris.
Last reviewed: 12 Jan 2016
CRUK internal database number: 320
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
